Certara, Inc. (NASDAQ:CERT) Given Average Recommendation of "Hold" by Analysts

Certara, Inc. (NASDAQ:CERT - Get Free Report) has earned a consensus rating of "Hold" from the eight research firms that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $15.92.

CERT has been the subject of a number of analyst reports. Barclays reduced their price objective on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday. Robert W. Baird decreased their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a report on Friday, September 27th.

Insider Activity

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company's stock, valued at $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. bought a new stake in Certara in the 2nd quarter valued at about $26,000. Innealta Capital LLC purchased a new position in shares of Certara in the second quarter valued at $36,000. KBC Group NV raised its stake in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new stake in Certara during the 2nd quarter worth about $152,000. Finally, Algert Global LLC bought a new stake in shares of Certara during the second quarter valued at about $156,000. 73.96% of the stock is owned by institutional investors.

Certara Stock Performance

Shares of CERT stock traded down $0.14 during mid-day trading on Monday, hitting $10.89. The company's stock had a trading volume of 1,042,206 shares, compared to its average volume of 787,603. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.86. The company's fifty day simple moving average is $11.02 and its 200-day simple moving average is $13.66. Certara has a 52 week low of $9.99 and a 52 week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the prior year, the firm earned $0.06 earnings per share. Certara's revenue was up 10.7% on a year-over-year basis. On average, equities research analysts forecast that Certara will post 0.27 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.